)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Day One Biopharmaceuticals (DAWN) investor relations material
Day One Biopharmaceuticals Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary5 Aug, 2025
Executive summary
OJEMDA net product revenue reached $33.6M in Q2 2025, up 310% year-over-year and 10% sequentially, with over 1,000 prescriptions and strong commercial momentum.
FDA approved OJEMDA in April 2024 for relapsed/refractory pLGG; commercial launch underway in the U.S.
Cumulative net revenue for the trailing twelve months reached $113.1M, surpassing initial launch expectations.
Entered Ipsen License Agreement for ex-U.S. commercialization, with $70.8M upfront, $40M equity investment, and EMA submission planned for Q1 2025.
Ended Q2 2025 with $453.1M in cash, cash equivalents, and short-term investments, and no debt.
Financial highlights
Q2 2025 net product revenue was $33.6M, up 10% sequentially and 310% year-over-year.
Year-to-date net product revenue reached $64.1M; trailing twelve-month revenue totaled $113.1M.
Q2 2025 total operating expenses were $68.9M, including $36.1M R&D and $29.0M SG&A, both down year-over-year.
Net loss for Q2 2025 was $30.3M, compared to $4.4M in Q2 2024, which included a $108M gain from a priority voucher sale.
Cash, cash equivalents, and short-term investments totaled $453.1M as of June 30, 2025.
Outlook and guidance
Full-year 2025 OJEMDA net product revenue is projected at $140M–$150M, implying about 150% year-over-year growth at the midpoint.
Patient enrollment for the pivotal Phase 3 FIREFLY-2 trial is on track for completion in H1 2026; three-year follow-up data from FIREFLY-1 expected in Q4 2025.
Guidance assumes steady increase in new patient starts and persistence on therapy; gross-to-net range expected at 12%–15%.
EMA regulatory submission for OJEMDA expected in Q1 2025; eligible for up to $380M in milestones and double-digit royalties from Ipsen.
Cash position expected to fund operations for at least 12 months from filing date.
Assess impact of VRK1 program termination.
Elaborate on DAY301 Phase 1a/b trial progress.
Explain the decrease in R&D expenses.
What factors drive 2025 revenue guidance?
How did ASCO data impact new scripts?
Comment on DAY301's dose escalation.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Day One Biopharmaceuticals earnings date
Q3 202529 Oct, 2025
Next Day One Biopharmaceuticals earnings date
Q3 202529 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Day One Biopharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancer patients. The company specializes in identifying and advancing therapies designed for patients with genetically defined cancers, particularly in pediatric and young adult populations. The company is headquartered in Brisbane, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage